Are you Dr. Mascola?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 75 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
National Naval Medical Ctr
8901 Rockville Pike
Bethesda, MD 20889Phone+1 301-295-4611Fax+1 301-480-2788- Is this information wrong?
Summary
- Dr. John Mascola, MD is an infectious disease specialist in Bethesda, Maryland. He is currently licensed to practice medicine in California.
Education & Training
- Naval Medical Center (San Diego)Residency, Internal Medicine, 1987 - 1989
- Naval Medical Center (San Diego)Internship, Internal Medicine, 1985 - 1986
- Georgetown University School of MedicineClass of 1985
Certifications & Licensure
- CA State Medical License 1987 - 2022
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2002
Publications & Presentations
PubMed
- Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.Seemal F Awan, Amarendra Pegu, Larisa Strom, Cristina A Carter, Cynthia S Hendel, LaSonji A Holman, Pamela J Costner, Olga Trofymenko, Renunda Dyer, Ingelise J Gordon,...> ;JCI Insight. 2024 Apr 8
- Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.Myra Happe, Amelia R Hofstetter, Jing Wang, Galina V Yamshchikov, LaSonji A Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F...> ;NPJ Vaccines. 2024 Mar 29
- Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer base.Duan, H., Corrigan, A., Cheng, C., Biju, A., Gonelli, C., Olia, A., Teng, I., Xu, K., O'Dell, S., Narpala, S., Castro, M., Serebryannyy, L., Wang, J., Parchment, D., S...> ;Iscience. 2024 Feb 16
- Join now to see all
Authored Content
- Epitope-Based Vaccine Design Yields Fusion Peptide-Directed Antibodies That Neutralize Diverse Strains of HIV-1June 2020
Press Mentions
- NIAID Vaccine R&D Director Who Collaborated with Moderna on COVID-19 Vaccine to RetireFebruary 16th, 2022
- Vaccine Makers Pursue Omicron-Targeted Shots That Health Officials Say Might Not Be NeededJanuary 14th, 2022
- Covid-19 Vaccine Makers Assess Omicron ResponseNovember 29th, 2021
- Join now to see all
Grant Support
- Isolation And Deep Sequencing Of Monoclonal Antiobodies Against HIVNational Institute Of Allergy And Infectious Diseases2011
- Determination Of The Neutralization Specificity In Broadly Neutralizing HIV SERANational Institute Of Allergy And Infectious Diseases2010–2011
- Preclinical Evaluation Of Neutralizing Antibodies Elicited By HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2009–2011
- Non-Human Primate Immunogenicity Studies Of HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2009–2011
- NON Human Primate Models Of SIV And HIV Immune ProtectionNational Institute Of Allergy And Infectious Diseases2009–2011
- Measurement Of HIV Neutralization Using Quantitative AssaysNational Institute Of Allergy And Infectious Diseases2009–2011
- Isolation Of Monoclonal Antiobodies Against HIVNational Institute Of Allergy And Infectious Diseases2009–2010
- Evaluation Of Antibody Specificities In Broadly Neutralizing HIV SERANational Institute Of Allergy And Infectious Diseases2009
- Measurement Of HIV Neutralization Using Quantitative AssaysNational Institute Of Allergy And Infectious Diseases2008
- Isolation Of Monoclonal Antiobodies Against HIVNational Institute Of Allergy And Infectious Diseases2008
- Evaluation Of Antibody Specificities In Broadly Neutralizing HIV SERANational Institute Of Allergy And Infectious Diseases2008
- Preclinical Evaluation Of Neutralizing Antibodies Elicited By HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2007–2008
- Non-Human Primate Immunogenicity Studies Of HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2007–2008
- NON Human Primate Models Of SIV And HIV Immune ProtectionNational Institute Of Allergy And Infectious Diseases2007–2008
- Measurement Of HIV Neutralization Using Flow Cytometric &Reporter Virus AssaysNational Institute Of Allergy And Infectious Diseases2007
- Non-Human Primate Immunogenicity Studies Of HIV-1 ImmunoNational Institute Of Allergy And Infectious Diseases2005–2006
- Measurement Of HIV Neutralization Using Flow CytometricNational Institute Of Allergy And Infectious Diseases2005–2006
- Macaque Studies Of Correlates Of HIV ProtectionNational Institute Of Allergy And Infectious Diseases2004–2006
- Preclinical Evaluation Of Neutralizing Antibodies ElicitNational Institute Of Allergy And Infectious Diseases2002–2006
- Evaluation Of Neutralizing Antibodies Elicited By HIV-1National Institute Of Allergy And Infectious Diseases2005
- Preclinical Evaluation Of HIV-1 Neutralizing AntibodiesNational Institute Of Allergy And Infectious Diseases2004
- Measurement Of HIV NeutralizationNational Institute Of Allergy And Infectious Diseases2004
- Immunogenicity Studies Of HIV-1 ImmunogensNational Institute Of Allergy And Infectious Diseases2004
- Optimizing Measurement Of HIV-1 Neutralization Using ANational Institute Of Allergy And Infectious Diseases2003
- Passive Antibody Protection In The Setting Of Active CELNational Institute Of Allergy And Infectious Diseases2002–2003
- Non-Human Primate Immunogenicity Studies Of DNA Prime, RNational Institute Of Allergy And Infectious Diseases2002–2003
- Optimizing Measurement Of HIV-1 Neutralization Using A FNational Institute Of Allergy And Infectious Diseases2002
- Passive Antibody Protection In SHIV Challenge ModelNational Heart, Lung, And Blood Institute1997–1999